Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils
Henry C. Lin(Oregon Health & Science University), Thomas B. Casale(University of South Florida), Calman Prussin(National Institutes of Health), K.M. Boesel(Creighton University), Robert G. Townley(Creighton University), Barbara A. Foster(Roswell Park Comprehensive Cancer Center), F.A. Romero(Creighton University), D.T. Griffith(Creighton University)
Cited by 267
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k